Robin Li, Baidu CEO, at the World Artificial Intelligence Conference (WAIC) in Shanghai, July 9, 2020 (Zhai Huiyong, Imaginechina via AP Images)

September 10, 2020 10:54 AM EDT

China

As China's tech giants catch onto biotech, Baidu plots $2B startup focused on diagnosis, AI drug discovery

Amber Tong

Senior Editor

When China’s biggest search engine builder forays into biotech, expect it to move in large strides.

Baidu is reportedly scouting around for investors to collectively put $2 billion behind a biotech startup that would leverage its artificial intelligence technologies in disease diagnosis and drug discovery — following in the footsteps of American tech giants while joining its Chinese counterparts in making healthcare investments.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

As China's tech giants catch onto biotech, Baidu plots $2B startup focused on diagnosis, AI drug discovery

Amber Tong

Senior Editor

Unlock this article instantly by becoming a free subscriber.

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Senators want to know more on why Novo is discontinuing its insulin Levemir

As Chi­na's tech gi­ants catch on­to biotech, Baidu plots $2B start­up fo­cused on di­ag­no­sis, AI drug dis­cov­ery

Amber Tong

Senior Editor

Unlock this article instantly by becoming a free subscriber.

more like this

J&J's AI head jumps to Re­cur­sion; Doug Williams re­signs as Sana's R&D chief

Rare neu­ro dis­or­der of­fers new area for com­pe­ti­tion, an­a­lysts say: #AAN24

CSL Vi­for pro­pos­es a mar­ket­ing cam­paign to set­tle Eu­ro­pean Com­mis­sion in­ves­ti­ga­tion

Ver­tex, Alpine’s IgAN drug has Hu­mi­ra-like po­ten­tial. But not all in­di­ca­tions are cre­at­ed equal

Take­da wins la­bel ex­pan­sion for sub­cu­ta­neous En­tyvio, cre­at­ing 'flex­i­bil­i­ty' for Crohn's pa­tients

Sen­a­tors want to know more on why No­vo is dis­con­tin­u­ing its in­sulin Lev­emir

As China's tech giants catch onto biotech, Baidu plots $2B startup focused on diagnosis, AI drug discovery

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Senators want to know more on why Novo is discontinuing its insulin Levemir